Webinars & Videos
View our curated collection of webinars and videos to learn more about Pluristyx's proprietary technologies and platforms, including FailSafe® and iACT Stealth Cells™, Ready-to-Differentiate® expansion, and cryopreservation development services.
The Next Big Thing in Pharma
Dr. Ben Fryer, Co-Founder and CEO of Pluristyx, talks to Pharma’s Almanac about pluripotent stem cells and how the company speeds up the R&D process by delivering Ready to Differentiate® cells.
A Safe Way of Cloaking Cells to Evade the Immune System (Dr. Andras Nagy)
A Safe Way of Cloaking Cells to Evade the Immune System | Andras Nagy, PhD, HonD, FRSC, Senior Investigator| Lunenfeld-Tanenbaum Research Institute, Sinai Health System; 25 Orde St, 5th floor, room 5-1015 | Toronto, ON, M5T 3H7 | Canada Video recording of Dr. Andras Nagy speaking at the ISCT (International Society of Cell& Gene Therapy) 2023 Annual Meeting
panCELLa FailSafe®
MAKING CELL THERAPY SAFE: Cell therapies are largely derived from induced pluripotent cells or embryonic cells and have the potential of reverting back to the original cell state or forming
A Failsafe® suicide gene-based system to improve safety & standardization of neural grafts (Parish)
Professor Clare Parish BBiomedSci, PhD; NHMRC Senior Research Fellow; Stem Cells and Neural Development laboratory; Florey Institute of Neuroscience & Mental Health; The University of Melbourne; Royal Pde, Parkville; Australia,
The Universal Cell: Making the Unsafe Safe (Dr. Andras Nagy)
The Universal Cell: Making the Unsafe Safe Andras Nagy, PhD, HonD, FRSC, Foreign Member of Hungarian Academy of Sciences; Shawn Kimel Research Scientist | Lunenfeld-Tanenbaum Research Institute, Sinai Health System;
Pluristyx Featured in Labroots Webinar
Dr. Ben Fryer, Co-Founder and CEO of Pluristyx, presented to webinar participants the “how and why” of integrating high quality ancillary raw materials into cell therapy product development and the manufacturing workflow, beginning with the starting cell source and MCB
Phacilitate - Humans of CGT
Dr. Brian Hawkins, Chief Technology Officer, Pluristyx, shares his thoughts on cell and gene therapy.
RegMedNet Interview
Dr. Brian Hawkins, Chief Technology Officer, Pluristyx, talks to RegMedNet about how protocols surrounding ATMP cryopreservation have changed over recent years. Dr. Hawkins focuses on the challenges of cryopreservation and discusses how programs readily adapt to the scale-up, tech transfer and late-stage clinical trials that occur during commercialization
ISCT Showcase –Cryopreservation Contact Services Development
Dr. Brian Hawkins, Chief Technology Officer, Pluristyx, introduces the company’s cryopreservation contract services.